PF-750
Piperidine urea that inhibits FAAH covalently and with complete selectivity among the serine hydrolases tested; founding compound of its class.
Harm-reduction warning
No characterised human dose: animal / in vitro data only. Effect profile, safety margin and acute toxicity are not documented in human clinical practice. Extremely potent compound: severe effects, seizures and deaths reported in the literature.
C₂₂H₂₃N₃O
CAS 959151-50-9
- Family
- ECS pharmacological toolEnzyme inhibitor
- Molar mass
- 345.40 g/mol
Updated on
In plain terms
PF-750 is a laboratory molecule that blocks the enzyme responsible for destroying anandamide, a messenger the body makes itself. Described in 2007, it was used to show that a chemical group considered very stable, the urea, could inactivate this enzyme by attaching to it, without touching the other enzymes of the same type that were tested. It remains a research tool, with no medical use and no consumer product.
Receptors and activity
Target network
- Blocks or inhibits
The lower the cited value, the closer the target sits to PF-750: one ring per factor of 100. A target with no measured value stays on the edge.
Where these targets live
Where each target has been found in humans, according to the cited studies. The map shows the target, not an effect of PF-750.
FAAHFAAH found in 7 regions of the body
- CortexpresentCortical pyramidal neurons1
- Basal gangliapresentStriatal neurons1
- HypothalamuspresentPresent in hypothalamic nuclei1
- CerebellumpresentPurkinje cells and cerebellar layers1
- BrainstempresentInferior olivary nuclei1
- Adipose tissuepresentExpressed in mature adipocytes2
- BonepresentPresent on osteoclasts3
Map sources
- Romero J et al. Fatty acid amide hydrolase localization in the human central nervous system: an immunohistochemical study. Brain Res Mol Brain Res, 2002 (new tab)
- Engeli S et al. Activation of the peripheral endocannabinoid system in human obesity. Diabetes, 2005 (new tab)
- Rossi F et al. The endovanilloid/endocannabinoid system in human osteoclasts: possible involvement in bone formation and resorption. Bone, 2009 (new tab)
Cited values
- FAAHInhibitorno measured value cited
time-dependent covalent inhibition (modification of the active-site nucleophilic serine); no IC50 value in the abstract of Ahn et al. 2007
Pharmacology
PF-750, together with PF-622, is the compound that introduced piperidine and piperazine ureas as a novel mechanistic class of FAAH inhibitors (Ahn et al. 2007). The finding was unexpected: the urea group is chemically very stable, yet both compounds inhibit the enzyme in a time-dependent manner by covalently modifying its nucleophilic serine. Activity-based proteomic profiling detects no inhibition of the other mammalian serine hydrolases. The authors attribute this selectivity, at least in part, to the special ability of FAAH to hydrolyse C(O)-N carbon-nitrogen bonds, whereas the vast majority of metabolic serine hydrolases in mammals are restricted to esters and thioesters (Ahn et al. 2007). PF-750 has remained a pharmacology tool; no pharmacokinetic, metabolic, toxicity or human dose data were found in the sources consulted.
Key sources.
- Ahn et al., Biochemistry 2007: a novel mechanistic class of FAAH inhibitors with remarkable selectivity (new tab)PMID 17949010
- PubChem, PF-750, CID 25154868 (identifiers and properties) (new tab)
- ANSM, consolidated list of narcotics, updated 16 February 2026 (text reviewed) (new tab)
- Council Framework Decision 2004/757/JHA, annex, consolidated version of 12 January 2026 (EUR-Lex) (new tab)
History
- Source
- Entirely synthetic compound with no known natural occurrence. It was described as a research compound (Ahn et al. 2007); no clinical development was found in the sources consulted.
Origin
Research tool
No known biosynthetic pathway: a chemically synthesised molecule. It is a piperidine urea, N-phenyl-4-(quinolin-3-ylmethyl)piperidine-1-carboxamide; PF-622 is its piperazine analogue carrying a quinolin-2-yl group (Ahn et al. 2007).
Legal framework
- European Union
The substance is not listed in the Annex to Council Framework Decision 2004/757/JHA (consolidated version of 12 January 2026), which lists the new psychoactive substances controlled at European Union level; control is a matter for national law. No marketing authorisation was found.
- France
Not classified: PF-750 does not appear in the ANSM consolidated list of narcotics (updated 16/02/2026); on a literal reading, its structure (a piperidine urea bearing a quinoline) falls within none of the generic families of Annex IV (indol-3-yl methanones, indazol-3-yl methanones, naphthoylpyrroles, indole or indazole carboxylates and carboxamides, cyclohexylphenols, benzo[c]chromene nucleus). No marketing authorisation was found.
Sources: EUR-Lex, UNODC, CND, ANSM, IUPHAR/BPS, ChEBI, EUDA. Our method.
Classification
Family, origin and source verification
- Family
ECS pharmacological tool › Enzyme inhibitor
- Verification
Classification, sources and binding values checked on 20 October 2026; text read against its sources and Wikipedia.
- Wikipedia (English)
No dedicated article.
References
- Ahn et al., Biochemistry 2007: a novel mechanistic class of FAAH inhibitors with remarkable selectivity (new tab)PMID 17949010
- PubChem, PF-750, CID 25154868 (identifiers and properties) (new tab)
- ANSM, consolidated list of narcotics, updated 16 February 2026 (text reviewed) (new tab)
- Council Framework Decision 2004/757/JHA, annex, consolidated version of 12 January 2026 (EUR-Lex) (new tab)
Identifiers
Names
- IUPAC name
- N-phenyl-4-(quinolin-3-ylmethyl)piperidine-1-carboxamide
- Other names
- PF 750 · PF750
Identifiers
- Formula
- C₂₂H₂₃N₃O
- CAS
- 959151-50-9
- PubChem CID
- 25154868(new tab)
- ChEBI
- 95037(new tab)
- InChIKey
- BIODYGOZWZNCAG-UHFFFAOYSA-N
- SMILES
- C1CN(CCC1CC2=
CC3= CC= CC= C3N= C2) C(= O) NC4= CC= CC= C4
LLM ingestion format: a structured superset of the entry (identifiers, binding, versioned legal status). Full corpus.